Milds Matter—Feasibility of Emicizumab Prophylaxis in Mild Hemophilia

Key Points

• Evaluate the feasibility of using emicizumab as a prophylactic treatment in individuals with mild hemophilia.
• Analysis of past data on emicizumab efficacy.
• Consultations with hemophilia experts for treatment insights.
• Consideration of patient feedback on treatment changes.
• Emicizumab shows promising potential in managing mild hemophilia.
• Patient adherence to prophylaxis is generally high.
• Fewer bleeding episodes reported compared to historical data.